XML 79 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
Note J - Revenue, Net (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Mar. 20, 2012
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
May 07, 2021
Revenue from Contract with Customer, Including Assessed Tax     $ 23,612 $ 27,461  
Arimoclomol Purchase Agreement [Member]          
Contract with Customer, Liability, Revenue Recognized     9,100 8,700  
Contract with Customer, Clawback Liability     5,700 5,100  
Asset Acquisition, Consideration Transferred, Estimated Reserve Liability     12,600 12,200  
License [Member] | AZSTARYS License Agreement [Member]          
Contract with Customer, Liability, Revenue Recognized   $ 15,000 4,300 18,500  
Deferred Revenue     0 0  
OLPRUVA [Member]          
Revenue from Contract with Customer, Including Assessed Tax     100 0  
MIPLYFFA [Member]          
Revenue from Contract with Customer, Including Assessed Tax     $ 10,100    
Commave Therapeutics SA [Member] | License [Member] | AZSTARYS License Agreement [Member]          
Revenue Recognition, Milestone Method, Additional Revenue to be Recognized         $ 590,000
Aquestive Therapeutics [Member] | License [Member] | AZSTARYS License Agreement [Member]          
Royalty Revenue, Percent 10.00%   10.00%    
Relief Therapeutics [Member] | License [Member]          
Contract with Customer, Liability, Revenue Recognized     $ 0    
Royalty Revenue, Percent     10.00%    
Contract with Customer, Liability     $ 0 $ 0